12 February 2018 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES − Invion announces fully underwritten non-renounceable rights issue to raise approximately $2.5 million before costs − Rights Issue forms part of the strategic transaction with The Cho Group announced on 31 August 2017 and approved by Invion shareholders at the AGM held 30…
Read more
Appendix 4C – December 2017 Quarter
29 January 2018 The Manager Company Announcements Office ASX Limited, 20 Bridge St, SYDNEY NSW 2000 Dear Sir APPENDIX 4C Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 31 December 2017. Funding The Company held cash reserves of $0.281 million at the end of December, with operating cash outflows…
Read more
Invion announces strategic transaction
Invion signs agreement with The Cho Group Limited to obtain exclusive commercialisation and distribution rights in Australia and New Zealand to NGPDT technologies for the treatment of all cancers Invion signs a global Research and Development Agreement to conduct clinical trials initially targeting prostate cancer The Cho Group will provide non-dilutive funding for all clinical…
Read more